Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Temozolomide (Primary) ; TRC 102 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 20 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2017.
- 20 Mar 2017 Status changed from recruiting to active, no longer recruiting.